Supplement Scholar
Nootropic / Neurotrophic

Dihexa

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Dihexa. Oral angiotensin IV analog with potent synaptogenic effects in preclinical models.

How it works. Potentiates hepatocyte growth factor (HGF) / c-Met signaling to drive dendritic spine formation and synaptogenesis.

What the research supports. 2 graded claims. Strongest: Oral bioavailability unusual for a peptide (preclinical).

Hormonal impact. Effects on HGF/c-Met signaling, BDNF pathway.

Side effects and interactions. 0 medication interactions listed. Serious: Theoretical concern: c-Met overactivation in oncology contexts.

Stacking. Pairs well with Cognitive training. Avoid combining with Active or recent cancer.

Common forms. Available as Oral, Transdermal (research).

Community. Experiences from people who have tried Dihexa. Anecdotes are not medical advice.

Dihexa. Oral angiotensin IV analog with potent synaptogenic effects in preclinical models.

Molecular structureC27H44N4O5 · 504.7 g/mol

What it is

Dihexa is an orally bioavailable hexapeptide derivative of angiotensin IV designed for blood-brain-barrier penetration and synaptogenic activity.

Also called

N-hexanoic-Tyr-Ile-(6) aminohexanoic amidePNB-0408

How it works

Potentiates hepatocyte growth factor (HGF) / c-Met signaling to drive dendritic spine formation and synaptogenesis.

Pathways

  • HGF/c-Met
  • Synaptogenesis
  • Angiotensin IV receptor binding

Effects

  • +Synaptogenesis in preclinical models supports
  • +Cognitive performance in animal AD models supports

What the research supports

Oral bioavailability unusual for a peptidepreclinical
Targets a synapse-formation pathway directlypreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑HGF/c-Met signalingincreases
~BDNF pathwaymodulates

Side effects & interactions

Common side effects

  • Limited human data — no profile established

Serious

  • Theoretical concern: c-Met overactivation in oncology contexts

No notable medication interactions listed.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Cognitive trainingActivity-dependent synaptic consolidation.

Avoid combining

  • Active or recent cancerc-Met signaling is implicated in several tumor types.

Common forms

  • Oral
  • Transdermal (research)

Discussion

Loading discussion…